Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831154 | 0.86 | LMNA (0.90) | LMNAKMT2AMAPTPDE4AGAA | |
| Simazine SCHEMBL8409822 | 0.86 | LMNA (1.00) | LMNAKMT2AMAPTPDE4AGAA | |
| Simazine SCHEMBL9130727 | 0.86 | LMNA (1.00) | LMNAKMT2AMAPTPDE4AGAA | |
| Simazine SCHEMBL37774 | 0.86 | LMNA (1.00) | LMNAKMT2AMAPTPDE4AGAA | |
| Simazine SCHEMBL28076157 | 0.84 | LMNA (0.95) | LMNAKMT2AMAPTPDE4AGAA | |
| SCHEMBL10308806 | 0.84 | LMNA (0.54) | LMNAKMT2AGAACYP1A2CYP2C19 | |
| SCHEMBL821681 | 0.84 | LMNA (0.61) | LMNAKMT2AGAACYP1A2CYP2C19 | |
| Simazine SCHEMBL23716534 | 0.82 | LMNA (0.91) | LMNAKMT2AMAPTPDE4AGAA | |
| Simazine SCHEMBL4731210 | 0.82 | LMNA (0.91) | LMNAKMT2AMAPTPDE4AGAA | |
| Simazine SCHEMBL9123386 | 0.82 | LMNA (0.91) | LMNAKMT2AMAPTPDE4AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019047909-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-03-14 | — | — | WO | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| EP-2391683-B1 | FIBER-REACTIVE COPPER COMPLEX DISAZO DYES | DYSTAR COLOURS DISTRIB GMBH (DE) | 2017-03-29 | — | — | EP | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20070113356-A1 | Reactive polysaccharide derivatives, their preparation and their use | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-05-24 | — | — | US | disclosed |
| US-5574037-A | MODULATED BY SINO-ATRIAL NODE, ANTIISCHEMIC AGENT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-11-12 | — | — | US | disclosed |
| EP-0431856-B1 | Heterocyclic compounds | ZENECA LTD (GB) | 1995-07-12 | — | — | EP | disclosed |
| US-5332737-A | Cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-07-26 | — | — | US | disclosed |
| EP-0431856-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070113356-A1 | Reactive polysaccharide derivatives, their preparation and their use | C1S, H1-0, H1-4 | LMNA 654/4885KMT2A 2501/4885MAPT 4550/4885 |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | LMNA 3954/4885KMT2A 2366/4885MAPT 3621/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | LMNA 4121/4885KMT2A 1452/4885MAPT 2247/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | LMNA 4289/4885KMT2A 1406/4885MAPT 2039/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | LMNA 3860/4885KMT2A 2717/4885MAPT 3911/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | LMNA 4289/4885KMT2A 1406/4885MAPT 2039/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | LMNA 3954/4885KMT2A 2366/4885MAPT 3621/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | LMNA 3954/4885KMT2A 2366/4885MAPT 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.